CD274 and neoplasm: Moreover, radiotherapy is being investigated in two ongoing clinical trials (NCT02959463, NCT03399552) as an additional approach aimed at potentiating the anti-tumor immune response induced by PD-1 (pembrolizumab) or PD-L1 (avelumab) blockade.